Hepatic Encephalopathy is the Key Driver of Symptom Burden in a Longitudinal Cohort of Patients With Advanced Chronic Liver Disease: PAL-LIVER Substudy.

Am J GastroenterolFeb 13, 2026 (epub)
Clinical ResearchGastroenterology

Elliot B Tapper, Christopher D Woodrell, Mina Rakoski et al.

✦ AI-curated · Sources linked

In 30 seconds

This secondary analysis of the 19-site PAL-LIVER cluster-randomized trial examined symptom and caregiver-burden trajectories among patients with decompensated cirrhosis and/or hepatocellular carcinoma. Of 935 enrolled patients, 823 had hepatic encephalopathy (HE) information, and 368 had HE at baseline. Across assessments extending to 12 months, symptom-burden trajectories were stable. HE was the strongest and most consistent independent predictor of high burden, including overall symptoms (odds ratio 1.83, 95% CI 1.38-2.41), depression, and caregiver burden.

Key findings

  • HE was associated with high overall symptom burden (Edmonton Symptom Assessment Scale odds ratio 1.83, 95% CI 1.38-2.41).
  • HE was associated with depression (Patient Health Questionnaire-9 odds ratio 1.93, 95% CI 1.44-2.60).
  • HE was associated with greater caregiver burden (Zarit Burden Interview-12 odds ratio 1.53, 95% CI 1.02-2.30).
  • Symptom trajectories remained stable over 12 months; caregiver burden was generally low and stable.

Why it matters

The findings identify HE as a consistent marker of physical, psychological, and caregiver burden in advanced liver disease. Recognising this relationship may help clinicians assess symptoms and caregiver needs alongside HE, rather than focusing only on liver-disease severity. The stable trajectories also suggest that high-burden subgroups may remain in need of support over time.

What to keep in mind

This was a secondary analysis of a trial, and the reported associations do not establish that HE causes symptom or caregiver burden.

Source

Published in Am J Gastroenterol. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Gastroenterology

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.